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Abstract
Background: Fragile-X-Mental-Retardation-1- (FMR1)-gene is supposed to be a key gene for ovarian reserve and
folliculogenesis. It contains in its 5’-UTR a triplet-base-repeat (CGG), that varies between 26 and 34 in general population.
CGG-repeat-lengths with 55–200 repeats (pre-mutation = PM) show instable heredity with a tendency to increase and are
associated with premature-ovarian-insufficiency or failure (POI/POF) in about 20%. FMR1-mRNA-expression in leucocytes
and granulosa cells (GCs) increases with CGG-repeat-length in PM-carriers, but variable FMR1-expression profiles were
also described in women with POI without PM-FMR1 repeat-length. Additionally, associations between low numbers
of retrieved oocytes and elevated FMR1-expression levels have been shown in GCs of females with mid-range
PM-CGG-repeats without POI. Effects of FMR1-repeat-lengths-deviations (n < 26 or n > 34) below the PM range (n < 55)
on ovarian reserve and response to ovarian stimulation remain controversial.
Methods: We enrolled 229 women undergoing controlled ovarian hyperstimulation for IVF/ICSI-treatment and
devided them in three ovarian-response-subgroups: Poor responder (POR) after Bologna Criteria, polycystic ovary
syndrome (PCO) after Rotterdam Criteria, or normal responder (NOR, control group). Subjects were subdivided into
six genotypes according to their be-allelic CGG-repeat length. FMR1-CGG-repeat-length was determined using
ALF-express-DNA-sequencer or ABI 3100/3130 × 1-sequencer. mRNA was extracted from GCs after follicular aspiration
and quantitative FMR1-expression was determined using specific TaqMan-Assay and applying the ΔΔCT method.
Kruskall-Wallis-Test or ANOVA were used for simple comparison between ovarian reserve (NOR, POR or PCO) and
CGG-subgroups or cohort demographic data. All statistical analysis were performed with SPSS and statistical
significance was set at p≤ 0.05.
Results: A statistically significant increase in FMR1-mRNA-expression-levels was detected in GCs of PORs with
heterozygous normal/low-CGG-repeat-length compared with other genotypes (p = 0.044).
Conclusion: Female ovarian response may be negatively affected by low CGG-alleles during stimulation. In addition,
due to a low-allele-effect, folliculogenesis may be impaired already prior to stimulation leading to diminished ovarian
reserve and poor ovarian response. A better understanding of FMR1 expression-regulation in GCs may help to elucidate
pathomechanisms of folliculogenesis disorders and to develop risk-adjusted treatments for IVF/ICSI-therapy. Herewith
FMR1-genotyping potentially provides a better estimatation of treatment outcome and allows the optimal adaptation
of stimulation protocols in future.
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Background
A sufficient ovarian reserve is crucial for female fertility
and, consequently, a successful pregnancy. Diminished
ovarian reserve can considerably affect the success rates of
assisted reproductive techniques (ARTs) [1]. The response
to controlled ovarian hyperstimulation, in addition to
oocyte quality, reflects female reproductive potential.
Therefore, understanding the mechanisms underlying
ovarian response patterns are necessary for improving
ART approaches.
FMR1 (fragile X mental retardation 1) gene is one of
the major genes of interest in this field, as it is associated
with premature ovarian insufficiency (POI) and its end-
point premature ovarian failure (POF; OMIM accession
number: 615723) and, as its protein FMRP is mainly local-
ized in granulosa cells within the ovary [2, 3]. The FMR1
gene contains a CGG repeat of variable size (generally, ap-
proximately 30 repeats long) in its 5′-untranslated region
(UTR) of exon 1 [4]. If the repeat length extends over 200
(full mutation: FM), individuals can develop the fragile X
syndrome (OMIM accession number: 300624), which is
linked with a mental retardation caused by FMR1 gene
silencing and loss of fragile X mental retardation 1 protein
(FMRP) [5]. While FM-carriers do not show an increased
risk for the development of POI/POF, premutation (PM)
carriers frequently (~ 20%) suffer from this disorder [2],
known as fragile X-associated POI (FXPOI) as well. They
have > 54 and < 200 CGG repeats in their FMR1 gene and
demonstrate a repeat length instability with a tendency of
increasing repeat lengths from one generation to the next.
In leukocytes and lymphoblastoid cells of male and
female FMR1 PM carriers, FMR1 mRNA was shown to be
overexpressed, while its protein level was decreased [6, 7].
This inverse correlation can be explained by the presence
of a regulatory feedback mechanism, where high
levels of FMR1 mRNA may be toxic and lead to the de-
velopment of pathologies in PM carriers [8]. For the
PM-associated neurological disorder FXTAS (fragile
X-associated tremor/ataxia syndrome) symptoms are ex-
plained by the formation of intranuclear inclusions by the
extended CGG triplet block, that result from aberrant
protein binding to specific hairpin structures within the
nucleus. Sequestration of the FMR1-PM mRNA thereby
leads to elevated transcription rates [9, 10]. Although simi-
lar results and mechanisms are expected in women with
POI as well, extensive studies on women and on female
germline cells have not been conducted. Previously, we
detected alterations in FMR1 expression levels in leuko-
cytes of women with POI, which were shown to be inde-
pendent of the PM status [3]. Chen et al. demonstrated that
CGG repeat length, regardless of the PM status, in human
neuronal and kidney cells may act as positive or negative
modulators of FMR1 translation [11]. Additionally, several
studies demonstrated that CGG repeats below 26 or above
34 may affect ovarian reserve and fertility as well [12–16].
According to the repeat lengths at both alleles (low < 26
repeats; normal 26–34 repeats; high 35–55 repeats) women
can be divided into six different FMR1-CGG-genotypes:
high/high, high/low, normal/high, normal/normal, normal/
low, and low/low [17]. A pathological effect of CGG repeats
outside the range of 26–34 repeats remains controversial,
since it was not observed in studies with different experi-
mental settings [18–22].
FMR1 expression levels in leukocytes and other cell
types may not be equivalent to the levels in germline cells.
During folliculogenesis, oocytes are surrounded by granu-
losa cells (GCs), forming a functional entity. These cells
are necessary for the proper development of oocytes be-
fore ovulation. In the human ovaries, GCs represent the
main source of FMRP [3], which led us to analyze FMR1
mRNA expression directly in human GCs, thereby avoid-
ing potential bias originating from the usage of animal
models or different human cell types or lines. This
study aimed to evaluate the effects of different FMR1
genotypes, according to the allele specific CGG repeat
length, on the expression of this gene in GCs in an
ovarian response-dependent manner.
Elizur et al. demonstrated a significant non-linear asso-
ciation between CGG repeat length and FMR1 expression
levels in GCs of female PM carriers, with the highest
FMR1 expression level in women with mid-range CGG
repeat length (80–120 triplets), which was shown to be
associated with a low number of oocytes retrieved during
in vitro fertilization (IVF) [23]. Mid-range PM carrier
status is also supposed to demonstrate the highest risk for
developing POI/POF in women [24].
To the best of our knowledge, association studies ana-
lyzing FMR1 mRNA expression profiles in GCs with aber-
rant FMR1 CGG repeat numbers below the PM threshold
have not been performed to date. Therefore, we evaluated
the effects of the six FMR1 genotypes (i.e. low, normal
and high repeat numbers for each allele) on the FMR1
mRNA expression profile in GCs, using GCs obtained
from women with different ovarian response patterns:
women with poor ovarian response (POR), women with
normal ovarian function (NOR), and women with polycys-
tic ovary syndrome (PCOS).
Methods
We aimed to evaluate if FMR1-CGG-repeat-lengths
aberrations from normal range (n: 26–34) influence the
mRNA-expression in GCs of women in an ovarian re-
sponse depending manner.
Study population
A total of 229 women that underwent controlled ovarian
hyperstimulation for either IVF or IVF with intracytoplas-
mic sperm injection (ICSI) treatment at the Department of
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Gynecological Endocrinology and Reproductive Medicine,
University Women’s Hospital, Heidelberg, from February
2013 to August 2016 were prospectively recruited for our
study. We collected GCs and blood samples from all
patients. Additionally, their medical records and question-
naires were assessed in order to obtain demographic infor-
mation (age at presentation and body mass index [BMI]),
baseline hormone levels (serum follicle stimulating hor-
mone [FSH], luteinizing hormone [LH], estradiol [E2], and
anti-Müllerian hormone [AMH]), and reproductive param-
eters (antral follicle count [AFC], total number of oocytes
recovered, and mature [MII] oocytes retrieved). Patients
were divided into three response groups. According to the
Bologna Criteria [25], patients were included into the POR
group (n = 70); in case of clinically documented PCOS,
according to the Rotterdam Criteria [26], patients were
included in the PCO group (n = 8). Those who did not
fulfill criteria for POR or PCO groups were included in the
NOR group, which served as a control (n = 151).
Ethical approval
All patients signed an informed consent form and com-
pleted a clinical questionnaire. This study was approved
by the local ethical committee of the University of
Heidelberg, Germany (number S-602/2013), and conducted
according to the principles expressed in the Declaration of
Helsinki.
CGG repeat length analysis
DNA samples were prepared as described previously [27]
from 10 ml of blood samples with EDTA. To analyze
CGG repeat length in the 5′-UTR of FMR1 exon 1, poly-
merase chain reaction (PCR) analysis and subsequent ana-
lysis of this region with the ALFexpress DNA sequencer
(Amersham 1050; Pharmacia Biotech, Freiburg, Germany)
or ABI 3100/3130xl sequencer (Life Technologies/Applied
Biosystems, Foster City, CA, USA) were performed. PCR
mixture (total volume, 30 ml) contained 0.25 μM of each
primer (for forward and reverse primer sequences see Fu
et al., 1991), 0.2 mM of dATP, dCTP, and dTTP each,
50 μM dGTP, 150 μM deaza-dGTP, 0.12 U KAPA Hot
Start Taq polymerase, 1× PCR buffer, 1.5 mM MgCl2,
1× Enhancer (Qiagen GmbH, Hilden, Germany), and
50 ng of genomic DNA. PCR conditions were as follows:
3 min at 94 °C for the first denaturation step; 35 cycles of
amplification with a time-temperature profile of 15 s at
94 °C, 15 s at 66 °C, 15 s at 72 °C; and the additional incu-
bation for 8 min at 72 °C in the last cycle. The forward pri-
mer was labeled with the fluorescent Cy5 or FAM dye
(Eurofins Genomics, Ebersberg, Germany). For the analysis
using ALFexpress sequencer, a 5 μl aliquot of PCR mix
was mixed with 5 μl of 6× loading solution (5 mg/ml Blue
Dextran (Carl Roth GmbH + Co. KG, Karlsruhe, Germany)
in formamide (Merck KGaA, Darmstadt, Germany)) and
1 μl of 250-bp internal marker. All samples following the
denaturation at 95 °C for 5 min were analyzed on 6% de-
naturing polyacrylamide gel with 7 M urea. A 70–397 nu-
cleotide size marker labeled with Cy5 dye was used for the
determination of CGG repeat numbers. Allele sizes and
peak areas of fluorescent products were analyzed with the
Fragment Manager software (Pharmacia Biotech, Freiburg,
Germany). To analyze the samples on the ABI 3100/3130xl
sequencer, 1 μl of PCR product was mixed with 10.5 μl of
Hi-Di-formamide and 0.5 μl of GeneScan ROX standard
(Applied Biosystems, Foster City, CA, USA) and loaded.
The obtained data were analyzed with the GeneMapper
software (Applied Biosystems, Foster City, CA, USA).
When the presence of PM was suspected, Southern blot
was performed using a-32P-dCTP radioactively-labeled p2
probe containing FMR1 exon 1 with CGG repeat as de-
scribed previously [28].
Non-PM allele length classification
A CGG repeat length of 26–34 was considered a normal re-
peat length range according to prior studies [4, 14–16, 20].
We classified the patients according to the repeat lengths at
both alleles (low < 26 repeats; normal 26–34 repeats; high
35–55 repeats) into six different genotypes: high/high,
high/low, normal/high, normal/normal, normal/low, and
low/low, as previously described [17]. PM carriers were not
included in the study.
Ovarian stimulation
Ovarian stimulation was performed using either the long
protocol of gonadotropin-releasing hormone (GnRH)
agonist administration (long GnRH agonist protocol) or
GnRH antagonist protocol. The appropriate protocol
was selected by the physicians in charge. In the long
GnRH agonist protocol an initial down-regulation using a
GnRH-agonist at day 20+ 1 of the menstrual cycle was
used. On day two of following cycle, gonadotropins
(mainly recFSH or HMG) were injected daily to induce
proper follicle maturation. When follicles reached 18 mm
diameter, ovulation was induced by HCG injection and
the oocytes were retrieved via ultrasound-guided follicular
puncture after 36 h in 14 ml round bottom tubes contain-
ing PBS (1× Phosphate-buffered saline) and heparin
(250 μl Heparin / 500 ml PBS). In the GnRH-antagonist
protocol, gonadotropins (mainly recFSH or HMG) were
injected daily to induce proper follicle maturation begin-
ning at day 2 of menstrual cycle. When the leading follicle
reached 14 mm average diameter, a GnRH-antagonist was
used to prevent preterm spontaneous ovulation. At stage
of 18 mm diameter follicle size, oocytes were retrieved
after ovulation induction as described above. The cumula-
tive dose of gonadotropins was determined based on the
patients’ response and the decisions made by the physi-
cians in charge.
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Retrieval of GCs
GCs were retrieved from the follicular fluid after the
transvaginal ultrasound-guided follicle puncture for IVF
treatment that was performed with an ovum aspiration
needle (Premium Fas Single Lumen, #4551 NS-AS1;
Gynétics Medical Products N.V., Lommel, Belgium) con-
nected to a vacuum pump (Cook Medical, K-MAR-5200,
Bloomington, IN, USA). The aspirated follicular fluid
was collected in 14 mL round-bottom tubes (Falcon,
352,001, NY, USA), and kept at 37 °C in a test-tube heater
(Cook Medical, K-FTH-1012, Bloomington, IN, USA) or
in a Thermo-Cell-Transporter (Labotect, Thermo-Cell-
Transporter 3018, Rosdorf, Germany). Follicular fluid was
transferred to a 100-mm cell culture dish (Thermo Fisher
Scientific, Nunc, Waltham, MA, USA) on a table heated
to 37 °C (Workstation L126 Dual, K-Systems, Birkerød,
Denmark). GCs were identified morphologically as epithe-
lial cell aggregates within the follicular fluid using a Nikon
SMZ1500 zoom-stereomicroscope (Nikon Instruments
Europe B.V., Amsterdam, Netherlands). In most cases
granulosa cells (GCs) were picked up directly from the fol-
licular fluid without additional washing. A brief washing
step in either Multipurpose Handling Medium (MHM) or
Sydney IVF Fertilization medium (Cook, K-SIFM-20,
Bloomington, IN, USA) was considered necessary, if the
follicular fluid was bloody. In some cases, i.e. bloody fol-
licular fluid and a lot of Cumulus-Oocyte-Complexes
(COCs), the MHM used for keeping COCs during the
search also became bloody. In those cases GCs were
briefly washed in Sydney IVF Fertilization medium that
was also used to wash COCs before in vitro culture. We
did not check for pH variations in Sydney IVF Fertilization
medium after washing GCs and therefore cannot exclude
a possible impact. However, only equilibrated Sydney IVF
Fertilization medium was used for washing of COCs. The
Sydney IVF Fertilization medium was then used immedi-
ately to wash GCs. Thus, the time during which Sydney
IVF Fertilization medium was used outside the CO2-incu-
bator was kept to a minimum.
Mural GCs were aspirated in a 2.5 μl volume with a
sterile tip (ep Dualfilter T.I.P.S. 10 μl S, Eppendorf,
Wesseling-Berzdorf, Germany), transferred to 1.5-ml tubes
(Sarstedt, Nümbrecht, Germany) pre-filled with 12–13 μl
of RNAlater stabilization solution (Ambion, AM7020, Life
Technologies, Carlsbad, CA, USA), and stored at 4 °C.
RNA extraction
GCs in the stabilizing solution were centrifuged at
5000×g for 5 min, and the supernatants were removed.
mRNA was directly isolated from the GCs using TRIzol
(Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions [29, 30] with PEQGOLD PHA-
SETRAP A 1.5 ml tubes (VWR International GmbH,
Darmstadt, Germany). mRNA was dissolved in RNAse-free
water and the concentration and purity were detected using
NanoDrop 2000c UV-spectrometer (NanoDrop Products,
Wilmington, DE, USA). cDNA samples were synthesized
after oligo-dT priming with SuperScript III First-Strand
Synthesis System (Invitrogen by Life Technologies,
Carlsbad, CA, USA) and the M-MLV Reverse Tran-
scriptase, RNase H Minus, Point Mutant (Promega,
Madison, WI, USA).
Gene expression analysis
TaqMan predesigned gene expression assays for FMR1
(Hs00924544_m1) and two housekeeping genes, HPRT and
TBP (Hs99999909_m1; Hs00427620_m1, respectively), as
well as the TaqMan universal PCR master mix were
purchased from Applied Biosystems (Life Technologies,
Carlsbad, CA, USA) and the experiments were performed
according to the manufacturer’s instructions. The samples
were analyzed in triplicates, and standard PCR conditions
were used, with Fast Forward 7500 real-time PCR-system
(Applied Biosystems, Life Technologies, Carlsbad, CA,
USA). Relative gene expression was analyzed using ΔΔCt
method [31]. cDNA obtained from the COV 434 granulosa
cells [32] was used as a calibrator in each run.
Statistical analysis
Data distribution was first determined by Shapiro-Wilk-
Test. For simple comparison between ovarian reserve-
(NOR, POR, or PCO) or CGG-subgroups, and the analysis
of cohort demographic data, Kruskall-Wallis test or analysis
of variance (ANOVA) were used. When statistically signifi-
cant differences were obtained between groups, a post hoc
test [Tukey’s honestly significant difference (HSD) or
Dunn’s tests] was performed to identify which of the ana-
lyzed subgroups differed. In order to adjust the significance
level, the Bonferroni correction was applied. Additionally,
the χ2-test, supplemented by the adjusted residuals, was
used for between- group comparisons (clinical ovarian re-
serve classification and genotype). Results are presented as
mean ± standard deviation (SD), or median and interquar-
tile range (percentile 25-percentile 75; respectively 1rst-3rd
quartile). For n < 3, the data are presented as median and
minimum and maximum value (minimum–maximum).
Statistical analyses were performed with SPSS (Statistical
Package for the Social Sciences V. 22.0; IBM Corporation,




Of 229 patients participating in our study, 151 were clas-
sified as NORs, 70 belonged to the POR group, while
eight patients were included in the PCO group (Table 1).
No differences in BMI and estradiol (E2) levels, diag-
nosed at early follicular phase, were determined between
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the ovarian response groups. The age of patients of the 3
response groups differed whereby PCO patients were
the youngest (Table 1).
As expected, FSH (p = 0.013), LH, AMH, AFC, the
number of total oocytes retrieved, and the number of
MII oocytes differed significantly (p < 0.001 for all; Table 1)
between these three groups, which demonstrated the ap-
propriate patient selection.
In the three groups treatment distribution between
IVF, ICSI and IVF/ICSI-splitting was comparable be-
tween NOR and PCO with 69.3%, respectively 62.5% for
ICSI-treatments and with 26.7%, respectively 25% for
IVF-treatments. However, in the POR group the percent-
age of IVF was higher (45.2%) and no splitting was per-
formed in our population.
FMR1 mRNA expression
Relative mRNA FMR1 expression in GCs did not differ
between the three response groups (p = n.s.; Table 1).
FMR1 genotype groups
Cohort demographics
To evaluate the potential effects of CGG repeat number
aberrations on ovarian response and/or mRNA FMR1 ex-
pression in human GCs of IVF/ICSI patients, we divided
the patients according to their allele CGG repeat lengths
into six genotype groups: high/high, high/low, normal/
high, normal/normal, normal/low, and low/low groups.
As age distribution in all genotype groups was similar, we
did not perform any further age-dependent analyses. FSH,
LH, AMH, AFC, the number of total oocytes retrieved, and
the number of MII oocytes did not differ between different
genotype groups (p = n.s. for all; Table 2).
Ovarian response
The correlation analysis of the CGG genotypes and three
ovarian response groups showed no significant differences
in genotype distribution (p = n.s.; Table 3), demonstrating
that different genotypes in general are not associated with
the ovarian response in our study population.
FMR1 mRNA expression
Different genotypes in general were not shown to be re-
lated with FMR1 expression levels (p = n.s.; Table 4).
However, analysis of FMR1 expression related to ovarian
response showed that the normal/low genotype in PORs
is significantly associated with an increase in FMR1 ex-
pression in GCs (p = 0.044; Table 4).
Further analysis of the different genotypes in POR group
demonstrated that the FMR1 expression in normal/low
genotype group is significantly different compared with
that in both normal/high or normal/normal genotype
groups (p = 0.008 and p = 0.027, respectively; Fig. 1).
Discussion
Poor ovarian response is one of the major factors limit-
ing the success rate of infertility treatments. FMR1 is
involved in folliculogenesis and the CGG repeat length
in PM range was shown to be associated with the devel-
opment of POI. An association between high FMR1
mRNA expression levels in GCs in mid-range FMR1
PM-carriers and the lowest total number of retrieved oo-
cytes during IVF, compared with the other analyzed
groups, was demonstrated already earlier [23] suggesting
that via the exact level of FMR1 expression ovarian re-
sponse may be judged.
Table 1 Cohort demographics
Demographic NOR POR PCO p value
n Median (P25-P75) n Median (P25-P75) n Median (P25-P75)
Age* 151 35.1 ± 4.2A 70 37.4 ± 4.6B 8 31.3 ± 3.8C 0.001
BMI 149 23.6 (20.5–27.3) 65 22.3 (20.7–25.4) 8 26.3 (20.9–32.1) 0.352
AFC 84 6 (4.5–9)A 35 2.5 (1.5–3.5)B 6 16.25 (12.1–20)C < 0.001
FSH (U/L) 137 7.2 (6–8.8)A 59 8.6 (6.1–11.1)B 7 6.1 (5.8–7.2)AB 0.013
LH (U/L) 139 5.3 (3.7–6.8)A 62 5.5 (3.5–6.5)A 8 12.9 (9.6–17.5)B < 0.001
Estradiol 133 43 (34.5–58.2) 59 49.2 (31.1–76.0) 8 41.7 (31.1–46.4) 0.810
AMH 142 2.47 (1.4–3.8)A 69 0.88 (0.5–1.1)B 8 9.37 (4.5–14.6)C < 0.001
Total oocytes 149 9 (6–13)A 64 3 (2–5.7)B 8 22 (4.2–36)A < 0.001
MII oocytes 117 7 (5–11)A 43 3 (2–5)B 6 16 (8–27.2)A < 0.001
FMR1 138 0.75 (0.5–1.2) 57 0.8 (0.5–1.2) 8 0.9 (0.46–1.43) 0.947
BMI body mass index, AFC antral follicle count, FSH follicle stimulating hormone, LH luteinizing hormone, AMH anti-Müllerian-hormone, MII oocytes, mature
oocytes, FMR1 fragile X mental retardation 1 gene relative gene expression in granulosa cells of the patients normalized by two house-keeping genes and a
granulosa cell calibrator (see MM-part for details)
All other values represent median values, with 1st and 3rd quartile parenthesized
Different letters in one row signify statistical difference
p values represent significance levels between normal responders (NOR), poor responders (POR), and polycystic ovarian syndrome group (PCO)
*Mean ± standard deviation
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Here, we aimed to analyze the effects of CGG repeat
length aberrations outside the PM stage on the FMR1
expression in human GCs, and its potential correlation
with different ovarian response patterns. We detected a
significant effect of normal/low CGG repeat length in
the POR group on gene expression with significantly ele-
vated FMR1 mRNA expression levels in this group.
The impact of different FMR1 CGG repeat lengths
below the PM range as a potentially important marker of
female fertility and ovarian response remains controver-
sial. Different results obtained by analyzing the non-PM
FMR1 GCC repeat lengths may be partially explained by
the difference in study endpoints. While some groups fo-
cused on ovarian reserve or response to ovarian stimula-
tion depending on different FMR1 CGG haplo- and
genotypes, others considered the age of menopause or
AMH-level as CGG-dependent factors [12–22]. Also, in
the pathogenesis of other folliculogenesis disorders the
CGG repeat length is supposed to be involved. In PCO pa-
tients with normal/low FMR1 genotype statistically, for
example, higher rates of autoimmunity and lower preg-
nancy rates were detected [33].
In our study the number of PCO patients included
was quite low and low alleles were not detected in our
PCO group. The low number of PCO in our study can
be explained by our clinical procedures, where in vitro
maturation (IVM) is the protocol of choice offered to
patients with PCO due to an increased risk of developing
ovarian hyperstimulation syndrome instead of the classical
IVF/ICSI treatment. Patients undergoing IVM treatment
were not included in this study. The exclusion of PCO pa-
tients from our analysis does not affect the demonstrated
results, leading to the same conclusions. Nevertheless, for
future studies consideration of FMR1-genotype dependent
FMR1-expression variations in GCs of PCO-patients, es-
pecially those with low alleles, may be promising, too.
Furthermore, one of the limitations of our study is,
that we did not specifically check for CGG mosaics.
Therefore, we cannot exclude existing mosaics in our
patients, unless it is described, that only 1% of cases are
affected by this [34].
Additionally, we opine that the discrepancies in distri-
bution of ART-treatments between NOR and PCO with
POR are of minor importance, since our study evaluated
the gene expression in GCs after follicular aspiration
prior to fertilization in dependence of ovarian response
and FMR1-genotype and not the reproductive outcome.
We here evaluated for the first time the putative ef-
fects of aberrant non-PM FMR1 CGG repeat numbers
on female fertility based on the individual FMR1 mRNA
gene expression levels in GCs, the FMR1 target cells in
the ovary, that are highly relevant for proper folliculo-
genesis and oocyte maturation. We thereby aimed to
help elucidate the controversially discussed impact of
Table 2 Cohort demographic analysis of groups formed according to FMR1 genotypes
All patients
Demographics high/high high/low high/normal normal/normal normal/low low/low p
valuen (P25-P75) n (P25-P75) n (P25-P75) n (P25-P75) n (P25-P75) n (P25-P75)
Agea 2 34 ± 5.6 3 28.6 ± 1.1 25 35.4 ± 4.4 123 35.7 ± 4.5 65 35.9 ± 4.7 8 36.3 ± 3.2 0.163
AFC 2 6 (6–6) 0 – 18 3 (1.8–7.1) 62 5.75 (3–9.12) 38 5 (3–6.1) 3 5.5 (3.5–10) 0.239
FSH 2 9.5 (6.6–12.4) 2 7.3 (6.9–7.7) 23 8.3 (6.1–10.9) 110 7.1 (5.7–8.7) 56 7.8 (6.2–9.3) 7 7.9 (5.2–10.3) 0.323
LH 2 9.2 (6.7–11.7) 3 4.8 (4.7–6.1) 24 5.7 (3.7–10.1) 113 5.4 (3.5–7.1) 56 5.3 (3.7–6.4) 8 4.9 (3.6–6) 0.338
Estradiol 2 55.8 (51.5–68.2) 3 47.3 (31.2–63.1) 23 45.6 (38.2–76) 108 40.6 (32.4–58.2) 54 43.6 (34.3–57.9) 7 55.7 (41.5–76) 0.372
AMH 2 1.24 (0.94–1.55) 2 2.49 (2.48–2.5) 25 0.88 (0.55–3.35) 120 1.86 (1.06–3.68) 59 1.87 (1.14–3.16) 8 1.37 (1.03–1.64) 0.426
Total oocyte
number
2 2.5 (2–3) 3 9 (7–14) 23 6 (2–14) 120 7 (4–12) 63 7 (5–12) 8 4.5 (3.2–6) 0.210
MII oocyte
number
2 2 (2–2) 2 6.5 (6–7) 16 6 (2–15) 92 6 (3–9) 49 6 (4.5–9) 5 5 (3–8.5) 0.739
BMI body mass index, AFC antral follicle count, FSH follicle stimulating hormone, LH luteinizing hormone, AMH anti-Müllerian-hormone, MII oocytes
mature oocytes.
aAge, mean ± standard deviation is presented
All other values are presented as median and 1st and 3rd quartile parenthesized
p values represent significance levels between the six evaluated FMR1 genotypes
Table 3 FMR1 genotype distribution in patients with different
ovarian response patterns
Frequencies NOR - n (%) POR - n (%) PCO - n (%)
high/high 1 (0.7) 1 (1.4) 0 (0.0)
high/low 3 (2.0) 0 (0.0) 0 (0.0)
high/normal 13 (8.7) 10 (14.5) 2 (25.0)
normal/normal 79 (53.0) 38 (55.1) 6 (75.0)
normal/low 47 (31.5) 18 (26.1) 0 (0.0)
low/low 6 (4.0) 2 (2.9) 0 (0.0)
NOR normal responders, POR poor responders, PCO polycystic ovary
syndrome patients
Ovarian response distribution among the six FMR1 genotypes (p = 0.54)
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CGG repeat length aberrations on female fertility and
ovarian reserve [12–22]. We believe that our findings
can contribute to resolve this contentious issue as it
combines FMR1-gene-expression analysis in GCs with
the ovarian response of patients. Our obtained results
herein are in line with our previously obtained data,
showing different PM-independent FMR1 expression
levels in POI patients [3].
As POR may be considered as a clinical stage puta-
tively leading to the development of POI, we used female
GCs and focused on women showing different response
to controlled ovarian stimulation, to evaluate the poten-
tial association between their FMR1 mRNA expression
and different FMR1 genotypes, together with different
ovarian response patterns directly in female germline.
We demonstrated that patients belonging to the POR
group, with a normal/low CGG genotype, show a signifi-
cantly increased FMR1 expression levels in GCs, compared
with those in the other genotype groups (normal/normal
and normal/high). Combined with NOR and PCO such an
effect was not detected. This can be due to the limited sam-
ple size. So we appreciate further studies to clarify this
issue. If such a low allele effect only in POR with larger
sample sizes persists, it can be hypothesized, that women
with a normal/low CGG repeat length FMR1 genotype suf-
fer from POR due to their elevated FMR1 mRNA expres-
sion levels that negatively affect the response to controlled
ovarian hyperstimulation. Alternatively, poor response of
these patients could be the visible endpoint of an already
impaired folliculogenesis whose proper process is depend-
ing on a sound FMR1/FMRP expression regulation. The
low-CGG-allele thereby putatively influences this expres-
sion regulation. This would be in line with the results
of a previous study, that showed in patients carrying
heterozygous low CGG repeat length alleles a signifi-
cantly increased percentage of poor-quality embryo
morphology and a lower potential of conceiving after
ART [35]. One possible mechanism explaining such a
Table 4 FMR1 mRNA gene expression levels in different FMR1 genotype and ovarian response groups (age-independent)
FMR1
Expression
high/high high/low high/normal normal/normal normal/low low/low p
valuen (P25-P75) n (P25-P75) n (P25-P75) n (P25-P75) n (P25-P75) n (P25-P75)
All patients 1a 0.309 3 0.32 (0.26–1.54) 21 0.67 (0.51–1.21) 109 0.73 (0.47–1.25) 59 0.84 (0.55–1.27) 8 0.68 (0.19–1.69) 0.475
NOR 1a 0.309 3 0.32 (0.26–1.54) 10 0.95 (0.53–1.47) 71 0.71 (0.48–1.25) 45 0.77 (0.52–1.09) 6 0.68 (0.16–1.9) 0.630
POR 0 – 0 – 9 0.56 (0.47–0.69) 32 0.78 (0.43–1.2) 14 1.1 (0.95–1.5) 2 0.77 (0.2–1.3) 0.044
PCO 0 – 0 – 2 1.05 (0.92–1.19) 6 0.83 (0.35–1.53) 0 – 0 – 0.505
Distribution of FMR1-expression in GCs among the six genotypes related to different ovarian response groups. Normal/low genotypes demonstrated elevated
FMR1 expression in case of poor response (p = 0.044)
aDescriptive analysis only, due to the number of patients
p values represent significance-levels between the six genotypes and are calculated as described in the Material and Method part
Fig. 1 FMR1 gene expression in poor responder group (POR) depending on FMR1 genotype. * Statistically different from high/normal group
(p = 0.008); # statistically different from normal/normal group (p = 0.027)
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low-allele effect only in POR may be a skewed X In-
activation, as it is described in PM carrier women
suffering from FXTAS (Fragile-X-Associated Tremor/
Ataxia Syndrome) l [36].
Due to the limited low/low genotype numbers in POR
(n = 2) and NOR (n = 6) we could not detect an effect on
the FMR1 mRNA expression in POR, neither in NOR
with two low alleles. So, if this effect is even more pro-
nounced when two low alleles are present, stays specula-
tive. To elucidate this further studies with larger sample
sizes are needed, that especially include more patients
with homozygous and heterozygous low alleles.
If the CGG repeat length acts as a positive or negative
modulator of the FMR1 translation, as previously hy-
pothesized [11], low CGG repeat numbers may induce
gene transcription in POR patients putatively via altered
binding capacity of transcriptional factors and/or other
regulatory elements such as non coding RNAs (micro-
RNAs, long non coding RNAs), variable CpG methylation
and histone modifications. Evaluating these factors in a
CGG repeat length depending setting with regards to al-
tered FMR1 expression levels would therefore be of major
interest in future studies.
The elevated FMR1 mRNA levels of POR with nor-
mal/low genotype, similar to the situation in female
PM-carriers, may also have a toxic effect and lead to al-
tered FMRP levels. Therefore, in future studies the level
of FMRP in dependence of FMR1 genotype, the level of
RNA and the ovarian response should be evaluated. In
such a study, altered FMRP-level as potential cause of the
poor response and negative effects on proper oocyte and
embryo development after fertilization might be identified.
So further experiments aiming at the reproductive out-
come depending on different genotypes, FMR1/FMRP ex-
pression level and ovarian response are advisable.
In conclusion, analysis of FMR1 expression in GCs ob-
tained from women with different ovarian reserves can
help to obtain a better insight into the FMR1/FMRP ex-
pression regulatory mechanism and its putative effects
on female fertility and folliculogenesis disorders. To the
best of our knowledge, we are the first group analyzing
the impact of the CGG genotype on the ovarian response
and FMR1 expression directly at the locus of interest in
GCs, although larger samples are needed to substantiate
the results of this pilot project. Also, functional studies are
needed that evaluate involved regulatory elements in order
to clarify if and how high mRNA-expression-level of
FMR1 and the CGG repeat length impact follicular matur-
ation and ovarian response.
Conclusions
Heterozygous low CGG repeat numbers are associated
with significantly elevated FMR1-expressions profiles in
granulosa cells of women with poor ovarian response. If
the genotype directly affects female ovarian response or,
if this low response is caused by impaired folliculogen-
esis prior to stimulation due to a low-allele-effect stays
speculative. Our results may contribute to a better un-
derstanding of FMR1 expression-regulation in GCs in
order to elucidate underlying pathomechanisms of differ-
ent folliculogenesis disorders and are potentially of value
to develop risk-adjusted treatments during IVF/ICSI
therapy, in which FMR1 genotyping provides the better
estimate of treatment outcome and allows the optimal
adaptation of stimulation protocols in future.
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